{
  "@context": "aku-v2",
  "@type": "syndrome",
  "@id": "vascular:malformations:vm-016-hemangioma",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-07T01:10:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "last_updated": "2026-01-07T01:10:00.000Z",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vascular-malformations",
    "type": "clinical_entity",
    "difficulty": "advanced",
    "importance": "high",
    "aku_id": "VM-016",
    "keywords": [
      "infantile hemangioma",
      "GLUT-1",
      "propranolol",
      "vascular tumor"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "vascular_malformations",
    "isNativeDomain": true
  },
  "content": {
    "statement": "vascular:malformations:vm-016-hemangioma is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Vascular-Malformations that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:malformations:vm-016-hemangioma helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:malformations:vm-016-hemangioma include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:malformations:vm-016-hemangioma."
    }
  },
  "clinical_features": {
    "epidemiology": {
      "incidence": "4-5% of infants",
      "risk_factors": [
        "Female (3:1)",
        "Premature",
        "Low birth weight",
        "Caucasian",
        "Multiple gestations"
      ],
      "location": "Head/neck 60%, trunk 25%, extremity 15%"
    },
    "natural_history": {
      "precursor": "Pale or telangiectatic patch at birth (30%)",
      "proliferation": "Rapid growth first 0-9 months",
      "involution": "Gradual over 1-10 years (10% per year rule)",
      "residua": "Fibrofatty tissue, telangiectasias, redundant skin"
    },
    "diagnosis": {
      "clinical": "Classic appearance and growth pattern",
      "GLUT1": "Immunohistochemistry positive (distinguishes from malformations)",
      "imaging": "Ultrasound or MRI if deep or atypical"
    },
    "high_risk_features": {
      "periocular": "Amblyopia, astigmatism, ptosis",
      "nasal_tip": "Cyrano nose deformity",
      "lip": "Feeding difficulties, cosmetic",
      "beard_distribution": "Screen for airway hemangioma",
      "large_facial": "Evaluate for PHACE syndrome",
      "ulcerated": "Pain, scarring, infection risk"
    },
    "PHACE_syndrome": {
      "P": "Posterior fossa malformations",
      "H": "Hemangioma (large facial, segmental)",
      "A": "Arterial anomalies (cerebrovascular)",
      "C": "Cardiac defects/coarctation",
      "E": "Eye abnormalities"
    },
    "treatment": {
      "observation": "Most involute spontaneously; appropriate for low-risk lesions",
      "propranolol": {
        "indication": "High-risk features or parent preference",
        "dosing": "1-3 mg/kg/day divided BID-TID",
        "initiation": "Start low, titrate up; monitor HR, BP, glucose",
        "duration": "6-12+ months, until involution established",
        "contraindications": "Heart block, reactive airway disease, hypoglycemia risk"
      },
      "surgery": "For residual deformity after involution; rarely primary treatment",
      "laser": "For residual telangiectasias"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Infantile Hemangioma"
    },
    "altLabel": [
      "Strawberry hemangioma",
      "Capillary hemangioma"
    ],
    "definition": {
      "@language": "en",
      "@value": "The most common vascular tumor of infancy, GLUT-1 positive, with a characteristic proliferative phase followed by spontaneous involution, treatable with propranolol when indicated."
    },
    "notation": "VM-016"
  },
  "relationships": {
    "prerequisites": [
      "vascular:malformations:vm-002-issva"
    ],
    "enables": [
      "vascular:malformations:vm-017-propranolol"
    ],
    "skos:broader": [
      "vascular:tumors"
    ],
    "skos:related": [
      "vascular:syndromes:PHACE"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:malformations:vm-016-hemangioma. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "pediatric surgeons",
      "dermatologists",
      "vascular surgeons"
    ],
    "estimated_time": "20min",
    "learning_objectives": [
      "Describe the natural history of infantile hemangioma",
      "Identify high-risk features requiring intervention",
      "Apply propranolol therapy appropriately",
      "Recognize PHACE syndrome"
    ],
    "clinical_pearls": [
      "GLUT-1 positive = infantile hemangioma (distinguishes from malformations)",
      "Propranolol is first-line for high-risk hemangiomas",
      "10% per year rule: hemangiomas involute ~10% per year",
      "BEARD distribution = screen for AIRWAY hemangioma",
      "PHACE: large facial hemangioma needs brain/heart/eye workup",
      "Most hemangiomas need only observation - 90% involute by age 9"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "codingSystem": "SNOMED-CT",
      "codeValue": "400210000",
      "description": "Infantile hemangioma"
    },
    {
      "codingSystem": "ICD-10-CM",
      "codeValue": "D18.00",
      "description": "Hemangioma unspecified site"
    }
  ]
}